Acceleron Pharma (NASDAQ: XLRN) releases its next round of earnings Thursday. Here's Benzinga's essential guide to Acceleron Pharma's Q2 earnings report.
Earnings and Revenue
Based on management's projections, Acceleron Pharma analysts modeled for a loss of 64 cents per share on sales of $3.8 million.
Acceleron Pharma reported a per-share loss of 77 cents when it published results during the same quarter last year. Sales in that period totaled $3 million. The analyst consensus estimate would represent a 16.88 percent decrease in the company's earnings. Revenue would be up 24.30 percent on a year-over-year basis. Here's how the company's reported EPS has stacked up against analyst estimates in the past:
|Quarter||Q1 2018||Q4 2017||Q3 2017||Q2 2017|
Over the last 52-week period, shares are up 35.4 percent. Given that these returns are generally positive, long-term shareholders should be content going into this earnings release. Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. Analysts have been rating Acceleron Pharma stock as Neutral. The strength of this rating has maintained conviction over the past three months.
Don't be surprised to see the stock move on comments made during its conference call. Acceleron Pharma's Q2 conference call is scheduled to begin at 5:00 p.m. ET and can be accessed here: http://investor.acceleronpharma.com/events-presentations
See more from Benzinga
- Motorola Solutions Q2 Earnings Outlook
- Acacia Communications Q2 Earnings Outlook
- Earnings Preview: Marriott Vacations
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.